IL-17 promotes keratinocyte proliferation via the downregulation of C/EBPα

Ma,Wei‑Yuan; Jia,Kun; Zhang,Yan

doi:10.3892/etm.2015.2939

IL-17 promotes keratinocyte proliferation via the downregulation of C/EBPα

Authors:
- Wei‑Yuan Ma
- Kun Jia
- Yan Zhang
View Affiliations

Affiliations: Department of Dermatology, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R.China, School of Medicine, Shandong University, Jinan, Shandong 250012, P.R.China
Published online on: December 16, 2015 https://doi.org/10.3892/etm.2015.2939
Pages: 631-636

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Psoriasis vulgaris is a common chronic inflammatory skin disease characterized by the hyperproliferation and abnormal differentiation of keratinocytes. CCATT/enhancer binding protein α (C/EBPα) is abundant in the epidermis and is associated with the proliferation of keratinocytes. However, the role of C/EBPα in the proliferation of keratinocytes and the pathogenesis of psoriasis vulgaris are yet to be elucidated. In the present study, using two-step immunohistochemistry, the expression levels of C/EBPα and Ki‑67 were examined in skin biopsies harvested from 30 patients with psoriasis vulgaris and 30 healthy control subjects. The proliferation index (PI) was calculated and the correlation between C/EBPα expression levels and the PI was assessed using Pearson's correlation coefficient. In addition, the effect on HaCaT immortalized human keratinocytic cells of treatment with various concentrations of interleukin (IL)-17 was investigated. Subsequently, cell proliferation rates were examined using a Cell Counting kit‑8 assay and the mRNA and protein expression levels of C/EBPα were analyzed using semiquantitative reverse transcription-polymerase chain reaction and western blotting, respectively, in order to analyze the effects of IL‑17 stimulation on C/EBPα expression levels. C/EBPα expression was predominantly detected in the cytoplasm of the keratinocytes and C/EBPα expression levels were significantly lower in the psoriatic lesions (P<0.05), as compared with the control group. An inverse correlation was detected between the expression levels of C/EBPα and the PI in the psoriatic lesions. Furthermore, a significant increase in the cell proliferation rate and significant reductions in the mRNA and protein expression levels of C/EBPα were detected in HaCaT cells following treatment with IL‑17. These results demonstrated that C/EBPα may act as a downstream target of IL‑17 and may be associated with the pathogenesis of psoriasis.

View Figures

View References

1	Bowcock AM and Kreuger JG: Getting under the skin: The immunogenetics of psoriasis. Nat Rev Immunol. 5:699–711. 2005. View Article : Google Scholar : PubMed/NCBI
2	Lynde CW, Poulin Y, Vender R, Bourcier M and Khalil S: Interleukin 17A: Toward a new understanding of psoriasis pathogenesis. J Am Acad Dermatol. 71:141–150. 2014. View Article : Google Scholar : PubMed/NCBI
3	Raychaudhuri SP: Role of IL-17 in psoriasis and psoriatic arthritis. Clin Rev Allergy Immunol. 44:183–193. 2013. View Article : Google Scholar : PubMed/NCBI
4	Nakajima K: Critical role of the interleukin-23/T-helper 17 cell axis in the pathogenesis of psoriasis. J Dermatol. 39:219–224. 2012. View Article : Google Scholar : PubMed/NCBI
5	Nerlov C: The C/EBP family of transcription factors: A paradigm for interaction between gene expression and proliferation control. Trends Cell Biol. 17:318–324. 2007. View Article : Google Scholar : PubMed/NCBI
6	Roe JS and Vakoc CR: C/EBPα: Critical at the origin of leukemic transformation. J Exp Med. 211:1–4. 2014. View Article : Google Scholar : PubMed/NCBI
7	Zaragoza K, Bégay V, Schuetz A, Heinemann U and Leutz A: Repression of transcriptional activity of C/EBPalpha by E2F-dimerization partner complexes. Mol Cell Biol. 30:2293–2304. 2010. View Article : Google Scholar : PubMed/NCBI
8	Johnson PF: Molecular stop signs: R egulation of cell-cycle arrest by C/EBP transcription factors. J Cell Sci. 118:2545–2555. 2005. View Article : Google Scholar : PubMed/NCBI
9	Oh WJ, Rishi V, Orosz A, Gerdes MJ and Vinson C: Inhibition of CCAAT/enhancer binding protein family DNA binding in mouse epidermis prevents and regresses papillomas. Cancer Res. 67:1867–1876. 2007. View Article : Google Scholar : PubMed/NCBI
10	Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E, Braun D and Banerjee S: Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 366:1190–1199. 2012. View Article : Google Scholar : PubMed/NCBI
11	Kagami S, Rizzo HL, Lee JJ, Koguchi Y and Blauvelt A: Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol. 130:1373–1383. 2010. View Article : Google Scholar : PubMed/NCBI
12	Reich K: Anti-interleukin-17 monoclonal antibody ixekizumab in psoriasis. N Engl J Med. 367:274–275. 2012. View Article : Google Scholar : PubMed/NCBI
13	Papp KA, Leonardi C, Menter A, Ortonne JP, Krueger JG, Kricorian G, Aras G, Li J, Russell CB, Thompson EH and Baumgartner S: Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 366:1181–1189. 2012. View Article : Google Scholar : PubMed/NCBI
14	Kim HR, Cho ML, Kim KW, Juhn JY, Hwang SY, Yoon CH, Park SH, Lee SH and Kim HY: Up-regulation of IL-23p19 expression in rheumatoid arthritis synovial fibroblasts by IL-17 through PI3-kinase-, NF-kappaB-and p38 MAPK-dependent signalling pathways. Rheumatology (Oxford). 46:57–64. 2007. View Article : Google Scholar : PubMed/NCBI
15	Gu C, Wu L and Li X: IL-17 family, Cytokines, receptors and signaling. Cytokine. 64:477–485. 2013. View Article : Google Scholar : PubMed/NCBI
16	Papp KA, Reid C, Foley P, Sinclair R, Salinger DH, Williams G, Dong H, Krueger JG, Russell CB and Martin DA: Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis, Results from a phase I, randomized, placebo-controlled trial. J Invest Dermatol. 132:2466–2469. 2012. View Article : Google Scholar : PubMed/NCBI
17	Ramji D and Foka P: CCAAT/enhancer-binding proteins: Structure function and regulation. Biochem J. 365:561–575. 2002. View Article : Google Scholar : PubMed/NCBI
18	Tada Y, Brena RM, Hackanson B, Morrison C, Otterson GA and Plass C: Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer. J Natl Cancer Inst. 98:396–406. 2006. View Article : Google Scholar : PubMed/NCBI
19	Seifeddine R, Dreiem A, Blanc E, Fulchignoni-Lataud MC, Le Frère Belda MA, Lecuru F, Mayi TH, Mazure N, Favaudon V, Massaad C, et al: Hypoxia down-regulates CCAAT/enhancer binding protein-alpha expression in breast cancer cells. Cancer Res. 68:2158–2165. 2008. View Article : Google Scholar : PubMed/NCBI
20	Tseng HH, Hwang YH, Yeh KT, Chang JG, Chen YL and Yu HS: Reduced expression of C/EBP alpha protein in hepatocellular carcinoma is associated with advanced tumor stage and shortened patient survival. J Cancer Res Clin Oncol. 135:241–247. 2009. View Article : Google Scholar : PubMed/NCBI
21	Shim M, Powers KL, Ewing SJ, Zhu S and Smart RC: Diminished expression of C/EBPalpha in skin carcinomas is linked to oncogenic Ras and reexpression of C/EBPalpha in carcinoma cells inhibits proliferation. Cancer Res. 65:861–867. 2005.PubMed/NCBI
22	Reckzeh K and Cammenga J: Molecular mechanisms underlying deregulation of C/EBPalpha in acute myeloid leukemia. Int J Hematol. 91:557–568. 2010. View Article : Google Scholar : PubMed/NCBI
23	Harris TE, Albrecht JH, Nakanishi M and Darlington GJ: CCAAT/enhancer-binding protein-alpha cooperates with p21 to inhibit cyclin-dependent kinase-2 activity and induces growth arrest independent of DNA binding. J Biol Chem. 276:29200–29209. 2001. View Article : Google Scholar : PubMed/NCBI
24	Wang GL, Shi X, Salisbury E, Sun Y, Albrecht JH and Smith RG: andT imchenko NA: Cyclin D3 maintains growth-inhibitory activity of C/EBPalpha by stabilizing C/EBPalpha-cdk2 and C/EBPalpha-Brm complexes. Mol Cell Biol. 26:2570–2582. 2006. View Article : Google Scholar : PubMed/NCBI
25	Rishi L, Hannon M, Salomè M, Hasemann M, Frank AK, Campos J, Timoney J, O'Connor C, Cahill MR, Porse B and Keeshan K: Regulation of Trib2 by an E2F1-C/EBPα feedback loop in AML cell proliferation. Blood. 123:2389–2400. 2014. View Article : Google Scholar : PubMed/NCBI
26	Datta J, Majumder S, Kutay H, Motiwala T, Frankel W, Costa R, Cha HC, MacDougald OA, Jacob ST and Ghoshal K: Metallothionein expression is suppressed in primary human hepatocellular carcinomas and is mediated through inactivation of CCAAT/enhancer binding protein alpha by phosphatidylinositol 3-kinase signaling cascade. Cancer Res. 67:2736–2746. 2007. View Article : Google Scholar : PubMed/NCBI